mutLBSgeneDB |
Gene summary for PIM2 |
Gene summary |
Basic gene Info. | Gene symbol | PIM2 |
Gene name | Pim-2 proto-oncogene, serine/threonine kinase | |
Synonyms | - | |
Cytomap | UCSC genome browser: Xp11.23 | |
Type of gene | protein-coding | |
RefGenes | NM_006875.3, | |
Description | pim-2 oncogenepim-2hproto-oncogene Pim-2 (serine threonine kinase)serine/threonine protein kinase pim-2serine/threonine-protein kinase pim-2 | |
Modification date | 20141207 | |
dbXrefs | MIM : 300295 | |
HGNC : HGNC | ||
Ensembl : ENSG00000102096 | ||
HPRD : 02244 | ||
Vega : OTTHUMG00000024132 | ||
Protein | UniProt: Q9P1W9 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_PIM2 | |
BioGPS: 11040 | ||
Pathway | NCI Pathway Interaction Database: PIM2 | |
KEGG: PIM2 | ||
REACTOME: PIM2 | ||
Pathway Commons: PIM2 | ||
Context | iHOP: PIM2 | |
ligand binding site mutation search in PubMed: PIM2 | ||
UCL Cancer Institute: PIM2 | ||
Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID | GO:0000082 | G1/S transition of mitotic cell cycle | 20307683 | GO:0006468 | protein phosphorylation | 18593906 | GO:0008285 | negative regulation of cell proliferation | 20307683 | GO:0043066 | negative regulation of apoptotic process | 18675992 |
Top |
Ligand binding site mutations for PIM2 |
Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.) : non-synonymous mutation on LBS, Circle size denotes number of samples. |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | E167 | D166V | LUAD | 1 | L38 | L38M | LUSC | 1 | L116 | L116F | SKCM | 1 | L170 | L170M | UCEC | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for PIM2 |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | L170 | L170M | -1.016144 | L38 | L38M | -0.99718224 | L116 | L116F | -0.59147248 | E167 | D166V | -0.43578738 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for PIM2 from PDB |
Top |
Differential gene expression and gene-gene network for PIM2 |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for PIM2 |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
umls:C0023467 | Leukemia, Myeloid, Acute | 4 | Biomarker |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for PIM2 |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Gene-centered drug-gene interaction network |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of PIM2 go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | HB1 | RUTHENIUM-PYRIDOCARBAZOLE-1 | 2iwi | B | L116 E167 L170 | 3YR | 2-(2,6-DIFLUOROPHENYL)-N-{4-[(3S)-PYRROLIDIN-3- YLOXY]PYRIDIN-3-YL}-1,3-THIAZOLE-4-CARBOXAMIDE | 4x7q | B | L116 E167 L170 | 3YR | 2-(2,6-DIFLUOROPHENYL)-N-{4-[(3S)-PYRROLIDIN-3- YLOXY]PYRIDIN-3-YL}-1,3-THIAZOLE-4-CARBOXAMIDE | 4x7q | A | L116 E167 L170 | HB1 | RUTHENIUM-PYRIDOCARBAZOLE-1 | 2iwi | A | L38 L116 E167 L170 |
Top |
Conservation information for LBS of PIM2 |
Multiple alignments for Q9P1W9 in multiple species |
LBS | AA sequence | # species | Species |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |